Voices of Chagas in the USA

Woman sitting at a tableAround 300,000 people have Chagas disease in the USA. Read the stories of people living with this silent disease in California.

DNDi uses global mobile data service developed by FIND to manage clinical data in the Democratic Republic of Congo

Clinician looking into a microscope

DNDi is piloting a global SIM card service designed by The Foundation for Innovative New Diagnostics (FIND) to send clinical trial data securely from several clinical sites in the Democratic Republic of Congo (DRC). SIMs are small cards containing chips that are used in mobile phones and other connected devices to transmit data over the Internet in a secure manner.

DNDi remembers Derrick Wong, highly valued Board member

Derrick Wong

It is with great sadness that DNDi has learned of the passing of Derrick Wong, a highly valued member of the DNDi Board of Directors for six years. Derrick was involved in the creation of DNDi in 2002 and 2003, and he served on the Board and chaired the Finance and Audit Committee from 2011 to 2018. He stepped down from his posts a year ago due to illness.

R&D Portfolio Update February 2019: DNDi Sleeping sickness programme

Lab technicians looking into microscope in a clinical working on sleeping sickness

Fexinidazole, the first all-oral treatment for both stages of HAT caused by T.b gambiense and DNDi’s first new chemical entity, was recommended by the European Medicines Agency in November and registered in Democratic Republic of Congo (DRC) in December 2018. The Phase II/III study on acoziborole opened new clinical sites in DRC and Guinea.

R&D Portfolio Update February 2019: DNDi Leishmaniasis programme

Leish patients in a hospital

In Africa, results of a Phase III study on HIV/VL in Ethiopia showed high efficacy of a new combination therapy for co-infected patients, a Phase III study began to test new combination treatment for visceral leishmaniasis, and a Phase II study testing new treatments for PKDL started in Sudan. In Asia, the results of an infectivity study in Bangladesh confirmed that PKDL acts as a reservoir for leishmaniasis infection, with implications for elimination efforts across South Asia. In Latin America, the Brazilian Ministry of Health is reviewing its treatment policy to consider the adoption of AmBisome as the country’s first-line visceral leishmaniasis treatment.

R&D Portfolio Update February 2019: DNDi Chagas disease programme

Chagas patient in the hospital with a nurse

A Phase II study of new benznidazole regimens was completed in 2018 with results coming in 2019. A Phase II study of fexinidazole, a new drug being tested for Chagas, completed patient recruitment in 2018. New diagnosis and treatment access projects were launched in Guatemala and Brazil, and the project in Colombia showed major increases in people tested in pilot areas.

R&D Portfolio Update February 2019: DNDi Mycetoma programme

Mycetoma patients sitting in front of a hospital

The first-ever double-blind, randomized clinical trial for fungal mycetoma, underway in Sudan, had enrolled 84 patients by January 2019, the threshold for interim analysis. The primary objective of the study is to demonstrate the superiority of fosravuconazole over the current standard, itraconazole.  

R&D Portfolio Update February 2019: DNDi Paediatric HIV programme

Little boy with paediatric HIV being measured by a nurse in a hospital

As development continues for a “4-in-1” fixed-dose combination (abacavir/lamivudine/ lopinavir/ritonavir) for young children, interim results of the LIVING study for an optimized “2-in-1” lopinavir/ritonavir paediatric formulation were released. The study – which enrolled over 1,000 children in sub-Saharan Africa – showed that 83% of children were virologically suppressed at 48 weeks, compared to 55% at the beginning of the study.

R&D Portfolio Update February 2019: DNDi Hepatitis C programme

HCV patient standing in the street

The first stage of the clinical trial in Malaysia and Thailand testing the ravidasvir/sofosbuvir combination showed excellent results in 301 chronically infected adults, as 97% of those enrolled were cured. Cure rates were notably high for the hardest-to-treat patients. Stage 2 of the study, to confirm the pangenotypic potential of the combination, has started.

DNDi endorses the global Call for Action to step up the fight against mycetoma

Mycetoma Call for Action signed at the Mycetoma Conference in Sudan

DNDi has joined partners from 35 countries attending the Sixth International Conference on Mycetoma in Khartoum, Sudan to endorse a ‘Call for Action’ to accelerate global efforts to address the plight of mycetoma patients. The Call for Action urges the global health community to work together with health ministries, multilateral agencies, research institutions, pharmaceutical companies, and other partners to address the devastating consequences of this highly neglected disease.